<p>德克萨斯州欧文 --（商业资讯）-- 达林成分公司（纽约证券交易所代码：DAR）今天宣布与 Tessenderlo 集团（布鲁塞尔证券交易所代码：TESB）签署了一项最终协议，将两家公司在胶原蛋白和明胶领域的业务合并为一家新公司，双方均无需现金或初始投资。此战略合作旨在创建一家顶级的胶原蛋白健康、保健和营养产品公司，以抓住全球胶原蛋白增长的机遇。</p>
<p>达林成分公司首次在 5 月份宣布了这一合资企业。拟议的新公司将结合达林成分公司的胶原蛋白和明胶业务（品牌为 Rousselot）与 Tessenderlo 集团的 PB Leiner 业务。达林成分公司将持有 85% 的控股权，Tessenderlo 集团将持有剩余的 15%。合并后，新公司的年收入预计约为 15 亿美元，明胶和胶原蛋白的总产能约为 20 万吨，分布在南美、北美、欧洲和亚洲的 22 个设施中。</p>
<p>随着时间的推移，两家公司的整合提供了实现协同效应和开发 Nextida 产品组合的重大机会，这些产品旨在提供针对性的健康益处，并为增加收益提供显著机会。</p>
<p>达林成分公司董事长兼首席执行官 Randall C. Stuewe 表示：“这一战略合作预计将为增长创造新的机会，同时扩大提升达林成分公司股东价值的选择。胶原蛋白仍然是我们食品部门增长最快的部分，凭借 PB Leiner 的优秀团队、资产和产品组合，我们在这个充满活力的市场中处于加速创新、规模和增长的良好位置。”</p>
<p>Tessenderlo 集团首席执行官 Luc Tack 补充道：“这一最终协议是为我们的合作伙伴关系构建更强大未来的重要一步。”</p>
<p>待监管批准后，交易预计将在 2026 年完成。</p>
<p><strong>关于达林成分公司</strong></p>
<p>作为循环经济的先驱，达林成分公司（纽约证券交易所代码：DAR）从动物农业和食品行业获取材料，并将其转化为有价值的成分，以滋养人类、饲养动物和作物，并为世界提供可再生能源。该公司在 15 个以上国家运营 260 多个设施，处理约 15% 的全球动物农业副产品，生产约 30% 的全球胶原蛋白（包括明胶和水解胶原蛋白），并且是可再生能源的最大生产商之一。欲了解更多信息，请访问 darlingii.com。关注我们的 LinkedIn。</p>
<p><strong>关于 Tessenderlo 集团</strong></p>
<p>Tessenderlo 集团是一个工业集团，专注于农业、价值化生物残余、机械、机械工程、电子、能源，并提供以水为重点的工业解决方案。该集团总部位于比利时，在 100 多个国家开展业务，拥有超过 7000 名员工的全球团队。</p>
<p><strong>关于前瞻性信息的警示声明：</strong></p>
<p>本公告可能包含 “前瞻性声明”，其中包括有关公司财务表现、计划、目标、战略、未来收益、现金流、表现及其他非历史信息的信息，包括有关与 Tessenderlo 共同成立的拟议合资公司的前景和预计表现的信息。当在本公告中使用时，词语 “预计”、“预期”、“项目”、“计划”、“意图”、“相信”、“将” 和这些词的变体或类似表达旨在识别前瞻性声明。所有前瞻性声明均基于当前的期望和信念以及各种假设。不能保证公司或与 Tessenderlo 共同成立的合资公司将实现这些期望或这些信念将被证明是正确的。有许多风险和不确定性可能导致实际结果与本公告中表达或暗示的前瞻性声明的结果有重大差异。许多因素，其中许多超出公司的控制，可能导致实际结果与前瞻性声明中表达的结果有重大差异。这些因素包括可能阻止公司完成与 Tessenderlo 的拟议交易或实现拟议交易预期收益的因素。其他风险因素包括在公司向证券交易委员会提交的文件中讨论的因素。任何前瞻性声明仅在作出之日有效，公司不承担更新任何前瞻性声明的义务，以反映作出之日后的事件或情况，或反映预期或未预期事件或情况的发生。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMDkyNjUzMjFyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMDkyNjUzMjFyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251209265321/en/</p>
<p><strong>达林成分公司联系方式</strong></p>
<p><strong>媒体：</strong></p>
<p>Jillian Fleming</p>
<p>全球传播总监</p>
<p>（972）541-7115；jillian.fleming@darlingii.com</p>
<p><strong>投资者：</strong></p>
<p>Suann Guthrie</p>
<p>投资者关系和全球事务高级副总裁</p>
<p>（469）214-8202；suann.guthrie@darlingii.com</p>
<p>来源：达林成分公司</p>

<p>达林成分公司与特森德洛集团签署了一项最终协议，将通过合并各自的胶原蛋白和明胶业务成立一家新公司。达林将持有 85% 的股份，而特森德洛将持有 15%。新公司旨在利用全球胶原蛋白的增长，预计年收入为 15 亿美元，产能为 20 万吨。该交易预计将在 2026 年完成，待监管机构批准</p>

<p>IRVING, Texas--(BUSINESS WIRE)--Darling Ingredients Inc. (NYSE: DAR) today announced the signing of a definitive agreement with Tessenderlo Group (XBRU: TESB) to combine the collagen and gelatin segments of their companies into a new company, requiring no cash or initial investment from either party. This strategic partnership aims to create a top-tier, collagen-based health, wellness and nutrition products company positioned to capitalize on global collagen growth.</p>
<div class="lb-trans"><p>德克萨斯州欧文 --（商业资讯）-- 达林成分公司（纽约证券交易所代码：DAR）今天宣布与 Tessenderlo 集团（布鲁塞尔证券交易所代码：TESB）签署了一项最终协议，将两家公司在胶原蛋白和明胶领域的业务合并为一家新公司，双方均无需现金或初始投资。此战略合作旨在创建一家顶级的胶原蛋白健康、保健和营养产品公司，以抓住全球胶原蛋白增长的机遇。</p>
</div><p>Darling Ingredients first announced the joint venture in May. The proposed new company will combine Darling Ingredients’ collagen and gelatin business, branded as Rousselot, with Tessenderlo Group’s PB Leiner business. Darling Ingredients will hold a majority, 85% ownership stake and Tessenderlo Group will hold the remaining 15%. The combination will result in a new company, initially with expected annual revenue of approximately $1.5 billion, and total gelatin and collagen capacity of about 200,000 metric tons across 22 facilities located in South America, North America, Europe and Asia.</p>
<div class="lb-trans"><p>达林成分公司首次在 5 月份宣布了这一合资企业。拟议的新公司将结合达林成分公司的胶原蛋白和明胶业务（品牌为 Rousselot）与 Tessenderlo 集团的 PB Leiner 业务。达林成分公司将持有 85% 的控股权，Tessenderlo 集团将持有剩余的 15%。合并后，新公司的年收入预计约为 15 亿美元，明胶和胶原蛋白的总产能约为 20 万吨，分布在南美、北美、欧洲和亚洲的 22 个设施中。</p>
</div><p>Over time, the integration of the two companies provides significant opportunities to realize synergies and develop the Nextida portfolio of products, which are designed to deliver targeted health benefits and provide a significant opportunity to increase earnings.</p>
<div class="lb-trans"><p>随着时间的推移，两家公司的整合提供了实现协同效应和开发 Nextida 产品组合的重大机会，这些产品旨在提供针对性的健康益处，并为增加收益提供显著机会。</p>
</div><p>“This strategic partnership is expected to create new opportunities for growth, while expanding options to enhance shareholder value for Darling Ingredients,” said Randall C. Stuewe, Chairman and Chief Executive Officer of Darling Ingredients. “Collagen continues to be the fastest-growing part of our food segment, and with PB Leiner’s talented team, assets and product portfolio, we are well positioned to accelerate innovation, scale and growth in this dynamic market.”</p>
<div class="lb-trans"><p>达林成分公司董事长兼首席执行官 Randall C. Stuewe 表示：“这一战略合作预计将为增长创造新的机会，同时扩大提升达林成分公司股东价值的选择。胶原蛋白仍然是我们食品部门增长最快的部分，凭借 PB Leiner 的优秀团队、资产和产品组合，我们在这个充满活力的市场中处于加速创新、规模和增长的良好位置。”</p>
</div><p>Luc Tack, Chief Executive Officer, Tessenderlo Group, added “This final agreement is an important step forward in building a stronger future for our partnership.”</p>
<div class="lb-trans"><p>Tessenderlo 集团首席执行官 Luc Tack 补充道：“这一最终协议是为我们的合作伙伴关系构建更强大未来的重要一步。”</p>
</div><p>Pending regulatory approvals, the transaction is expected to close in 2026.</p>
<div class="lb-trans"><p>待监管批准后，交易预计将在 2026 年完成。</p>
</div><p><strong>About Darling Ingredients</strong></p>
<div class="lb-trans"><p><strong>关于达林成分公司</strong></p>
</div><p>A pioneer in circularity, Darling Ingredients Inc. (NYSE: DAR) takes material from the animal agriculture and food industries, and transforms them into valuable ingredients that nourish people, feed animals and crops, and fuel the world with renewable energy. The company operates over 260 facilities in more than 15 countries and processes about 15% of the world’s animal agricultural by-products, produces about 30% of the world’s collagen (both gelatin and hydrolyzed collagen), and is one of the largest producers of renewable energy. To learn more, visit darlingii.com. Follow us on LinkedIn.</p>
<div class="lb-trans"><p>作为循环经济的先驱，达林成分公司（纽约证券交易所代码：DAR）从动物农业和食品行业获取材料，并将其转化为有价值的成分，以滋养人类、饲养动物和作物，并为世界提供可再生能源。该公司在 15 个以上国家运营 260 多个设施，处理约 15% 的全球动物农业副产品，生产约 30% 的全球胶原蛋白（包括明胶和水解胶原蛋白），并且是可再生能源的最大生产商之一。欲了解更多信息，请访问 darlingii.com。关注我们的 LinkedIn。</p>
</div><p><strong>About Tessenderlo Group</strong></p>
<div class="lb-trans"><p><strong>关于 Tessenderlo 集团</strong></p>
</div><p>Tessenderlo Group is an industrial group that focuses on agriculture, valorizing bio-residuals, machinery, mechanical engineering, electronics, energy, and providing industrial solutions with a focus on water. With its headquarters in Belgium, the group is active in over 100 countries and has a global team of more than 7,000 employees.</p>
<div class="lb-trans"><p>Tessenderlo 集团是一个工业集团，专注于农业、价值化生物残余、机械、机械工程、电子、能源，并提供以水为重点的工业解决方案。该集团总部位于比利时，在 100 多个国家开展业务，拥有超过 7000 名员工的全球团队。</p>
</div><p><strong>Cautionary Statements Regarding Forward-Looking Information:</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性信息的警示声明：</strong></p>
</div><p>This release may contain “forward-looking statements,” which include information concerning the Company’s financial performance, plans, objectives, goals, strategies, future earnings, cash flow, performance and other information that is not historical information, including information concerning the outlook and projected performance of the proposed joint venture company to be formed with Tessenderlo. When used in this release, the words “expects,” “anticipates,” “projects,” “plans,” “intends,” “believes,” “will” and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the Company or the joint venture company to be formed with Tessenderlo will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the results expressed or implied by the forward-looking statements contained in this release. Numerous factors, many of which are beyond the Company’s control, could cause actual results to differ materially from those expressed as forward-looking statements. These include factors which could preclude the Company from closing the proposed transaction with Tessenderlo or realizing the anticipated benefits of the proposed transaction. Other risk factors include those that are discussed in the Company’s filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.</p>
<div class="lb-trans"><p>本公告可能包含 “前瞻性声明”，其中包括有关公司财务表现、计划、目标、战略、未来收益、现金流、表现及其他非历史信息的信息，包括有关与 Tessenderlo 共同成立的拟议合资公司的前景和预计表现的信息。当在本公告中使用时，词语 “预计”、“预期”、“项目”、“计划”、“意图”、“相信”、“将” 和这些词的变体或类似表达旨在识别前瞻性声明。所有前瞻性声明均基于当前的期望和信念以及各种假设。不能保证公司或与 Tessenderlo 共同成立的合资公司将实现这些期望或这些信念将被证明是正确的。有许多风险和不确定性可能导致实际结果与本公告中表达或暗示的前瞻性声明的结果有重大差异。许多因素，其中许多超出公司的控制，可能导致实际结果与前瞻性声明中表达的结果有重大差异。这些因素包括可能阻止公司完成与 Tessenderlo 的拟议交易或实现拟议交易预期收益的因素。其他风险因素包括在公司向证券交易委员会提交的文件中讨论的因素。任何前瞻性声明仅在作出之日有效，公司不承担更新任何前瞻性声明的义务，以反映作出之日后的事件或情况，或反映预期或未预期事件或情况的发生。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMDkyNjUzMjFyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251209265321r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251209265321/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251209265321/en/</p>
</div><p><strong>Darling Ingredients Contacts</strong></p>
<div class="lb-trans"><p><strong>达林成分公司联系方式</strong></p>
</div><p><strong>Media:</strong></p>
<div class="lb-trans"><p><strong>媒体：</strong></p>
</div><p>Jillian Fleming</p>
<div class="lb-trans"><p>Jillian Fleming</p>
</div><p>Director, Global Communications</p>
<div class="lb-trans"><p>全球传播总监</p>
</div><p>(972) 541-7115; jillian.fleming@darlingii.com</p>
<div class="lb-trans"><p>（972）541-7115；jillian.fleming@darlingii.com</p>
</div><p><strong>Investors:</strong></p>
<div class="lb-trans"><p><strong>投资者：</strong></p>
</div><p>Suann Guthrie</p>
<div class="lb-trans"><p>Suann Guthrie</p>
</div><p>Senior VP, Investor Relations and Global Affairs</p>
<div class="lb-trans"><p>投资者关系和全球事务高级副总裁</p>
</div><p>(469) 214-8202; suann.guthrie@darlingii.com</p>
<div class="lb-trans"><p>（469）214-8202；suann.guthrie@darlingii.com</p>
</div><p>Source: Darling Ingredients Inc.</p>
<div class="lb-trans"><p>来源：达林成分公司</p>
</div>

Darling Ingredients and Tessenderlo Group Sign Definitive Agreement to form New Company to Accelerate Growth in Attractive Collagen-Based Health, Wellness and Nutrition Sector | DAR Stock News

Darling Ingredients 和 Tessenderlo 集团签署了最终协议，成立一家新公司，以加速在有吸引力的胶原蛋白健康、保健和营养领域的增长 | DAR 股票新闻